Thursday, February 2, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

RFI – Advance Development of Broad Spectrum Countermeasures

by Global Biodefense Staff
April 11, 2014

The Department of Defense seeks to identify candidate medical countermeasures and supporting technologies for the Emerging Infectious Diseases Therapeutics (EID Tx) program.

The EID Tx program is seeking to develop Food and Drug Administration (FDA)-approved broad spectrum medical countermeasure (MCM) for protection against naturally occurring or biologically engineered viruses.

If an MCM candidate meets only some or portion of the criteria, or otherwise has capabilities not specifically called out by the criteria as stated in Purposes and Objectives (A through L) below, EID Tx still strongly encourages a response to this RFI so that a more complete understanding of the state-of-the-art may be obtained.

Respondents are asked to provide information on:

  • Efficacy data against any virus (non-human primates, other species, in vitro)
  • Route of administration (oral, intramuscular, inhalation, other)
  • Clinical trials completed for any indication or Investigational New Drug (IND)
  • Shelf life of drug product in years supported by cGMP stability studies
  • Number and type of pharmacologically relevant animal models in agents targeted
  • Storage requirements as demonstrated by cGMP studies (room temperature, refrigerated, frozen)
  • Number of treatment courses produced in a single manufacturing run
  • Estimated cost per treatment course
  • Therapeutic index in species in which efficacy testing for virus was carried out
  • Estimated number of months before New Drug Application (NDA) for any indication
  • Estimated number of months until IND can be submitted for any virus indication
  • Any associated intellectual property rights or patent coverage

The effort is managed by the Joint Product Manager Biological Defense-Therapeutics (JPdM BD-Tx), part of the Joint Project Manager Medical Countermeasures Systems (JPM-MCS), which is part of the Joint Program Executive Office for Chemical and Biological Defense.

Further details are available under Solicitaion Number: HDTRA1-14-JPM-0001. The response deadline is May 5, 2014.

Tags: Animal ModelsAntimicrobialsAntitoxinsAntiviralsJPEO-CBRNDRFIVaccines

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC